First ever tumor imaging technology that allows high throughput screening of drugs on live metastasizing tumor tissue samples in the lab. In the near term, this will answer a strong demand from researchers to increase anti-cancer drug discovery throughput. Our technology increases throughput by 100 times.
In the long term, this could allow personalized cancer treatment (multi-billion dollar market).
Despite over $15 billion spent per year in cancer drug research, the successful introduction of new anti-cancer drugs has nearly come to a halt over the past several years. We are changing this sad fact.
A leading German biotech company has licensed our technology and plans to bring this to market by the end of 2014. Also we have a partnership with the leading cancer clinic in the world, MD Anderson to advance the technology even further.